期刊
BLOOD
卷 117, 期 1, 页码 316-322出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-07-294629
关键词
-
类别
资金
- National Cancer Institute (NCI) [U24-CA76518, 5U01HL069294]
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL069294]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- NCI [5U01HL069294]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen Inc
- Astellas Pharma US Inc
- Baxter International Inc
- Bayer HealthCare Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- BioMarin Pharmaceutical Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Buchanan Family Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc
- CytoTherm
- DOR BioPharma Inc
- Dynal Biotech, an Invitrogen Company
- Eisai Inc
- Enzon Pharmaceuticals Inc
- European Group for Blood and Marrow Transplantation
- Gamida Cell Ltd
- GE Healthcare
- Genentech Inc
- Genzyme Corporation
- Histogenetics Inc
- HKS Medical Information Systems
- Hospira Inc
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co Ltd
- Leukemia & Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- MGI Pharma Inc
- Michigan Community Blood Centers
- Millennium Pharmaceuticals Inc
- Miller Pharmacal Group
- Milliman USA Inc
- Miltenyi Biotec Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics Inc
- Otsuka America Pharmaceutical Inc
- Pall Life Sciences
- Pfizer Inc
- Saladax Biomedical Inc
- Schering Corporation
- Society for Healthcare Epidemiology of America
- Soligenix Inc
- StemCyte Inc
- StemSoft Software Inc
- Sysmex America Inc
- THERAKOS Inc
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals Inc
- ViraCor Laboratories
- ViroPharma Inc
- Wellpoint Inc.
Risks of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT) recipients who receive conditioning without total body irradiation are not well known. We evaluated the incidence and risk factors for solid cancers after HCT using high-dose busulfan-cyclophosphamide conditioning in 4318 recipients of first allogeneic HCT for acute myeloid leukemia in first complete remission (N = 1742) and chronic myeloid leukemia in first chronic phase (N = 2576). Our cohort represented 22 041 person-years at risk. Sixty-six solid cancers were reported at a median of 6 years after HCT. The cumulative- incidence of solid cancers at 5 and 10 years after HCT was 0.6% and 1.2% among acute myeloid leukemia and 0.9% and 2.4% among chronic myeloid leukemia patients. In comparison to general population incidence rates, HCT recipients had 1.4 x higher than expected rate of invasive solid cancers (95% confidence interval, 1.08-1.79, P = .01). Significantly elevated risks were observed for tumors of the oral cavity, esophagus, lung, soft tissue, and brain. Chronic graft-versus-host disease was an independent risk factor for all solid cancers, and especially cancers of the oral cavity. Recipients of allogeneic HCT using busulfan-cyclophosphamide conditioning are at risk for developing solid cancers. Their incidence continues to increase with time, and lifelong cancer surveillance is warranted in this population. (Blood. 2011;117(1):316-322)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据